Articles

Global advances and future directions in lung cancer care: expert consensus and strategic priorities

ML. Meyer, S. Peters, PA Jänne, TS Mok. Et al. ESMO Open. 2026 Feb;11(2):106034

Over the past decade, lung cancer management has been reshaped by advances in early detection, treatment, and prevention. Prevention now extends beyond tobacco control to include recognition of non-tobacco risk factors, screening, and incidental nodule programs. Yet progress in primary prevention remains uneven, with m... Read More

24 Mar, 2026

Disease burden of trachea, bronchus and lung cancer 1990-2021 and global trends projected to 2035

Xin Zhang, Jing Zou, Jinghua Ning,et al. Sci Rep. 2025 Feb 20;15(1):6264

Tracheal, bronchial, and lung cancer (TBL) is among the most common malignancies worldwide, with persistently high incidence and mortality rates, posing a significant threat to public health. This study comprehensively evaluated the global, regional, and national burden of TBL across 204 countries and territories from ... Read More

24 Mar, 2026

Global burden of lung cancer in 2022 and projected burden in 2050

Lanwei Guo, Chenxin Zhu, Lin Cai, et al. Lanwei Guo, Chenxin Zhu, Lin Cai, et al. Chinese Medical Journal 2024;137(21)

Lung cancer is the most common cancer and a leading cause of cancer-related deaths globally. The aim of this study was to evaluate the incidence and mortality of lung cancer worldwide in 2022 and to project the number of new cases and deaths due to lung cancer in China and the United States in 2050. Globally, an estima... Read More

24 Mar, 2026

Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis

Yixin Zhou, Anlin Li, Hui Yu, et al. JAMA Netw Open. 2024 Mar 4;7(3):e241285

Neoadjuvant therapy combining programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors with platinum-based chemotherapy has demonstrated significant improvement in pathologic response and survival rates among patients with resectable non-small cell lung cancer (NSCLC). However, it remains controv... Read More

24 Mar, 2026

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Christian U Blank, Minke W Lucas, Richard A Scolyer, et al. N Engl J Med. 2024 Nov 7;391(18):1696-1708

In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% in the neoadjuvant group... Read More

24 Mar, 2026

Nonoperative Management of Mismatch Repair-Deficient Tumors

Andrea Cercek, Michael B Foote, Benoit Rousseau, et al. N Engl J Med. 2025 Jun 19;392(23):2297-2308

Among patients with mismatch repair-deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this approach can be extended to all early-stage dMMR solid tumors, regardless of tumor site, is unknown. We conducted a phase 2... Read More

24 Mar, 2026

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

Suzanne L Topalian, Patrick M Forde, Leisha A Emens,et al.   Cancer Cell. 2023 Sep 11;41(9):1551-1566

Among new treatment approaches for patients with cancer, few have accelerated as quickly as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is administered before curative-intent surgery in treatment-naïve patients. Conventional neoadjuvant chemotherapy and radiotherapy are primarily intended t... Read More

24 Mar, 2026

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization

Douglas B. Johnson, Amin H. Nassar, Ayesha Aijaz,et al. Nat Rev Clin Oncol 2026 Feb 18.

Anti-PD-L1 antibodies have transformed cancer treatment and are increasingly being used in patients with early-stage malignancies including in the adjuvant and neoadjuvant settings. In this Review, we explore the optimal use of anti-PD-L1 antibodies in the adjuvant and perioperative settings, using examples from melano... Read More

24 Mar, 2026

Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice

Ivone U S Leong, Claudia P Cabrera, Valentina Cipriani, et al.J Clin Oncol. 2025 Feb 20;43(6):682-693

As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service. We identified clinically relevant PGx v... Read More

24 Mar, 2026

Germline Testing in Patients with Breast Cancer: ASCO–Society of Surgical Oncology Guideline

Isabelle Bedrosian, Mark R. Somerfield, Maria Isabel Achatz, et al. J. Clin Oncol 2024 Feb 10;42(5):584-604

An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. Forty-seven articles met eligibility criteria for the germline mutation testing recommendations: 18 for the genetic counseling recommendations. BRCA1/2 mutation testing should ... Read More

24 Mar, 2026